Usually yes, they do. But it’s not really just the company, it is the researchers. The other trials we have been discussing, that are being used fir historical comparison, some are in published research journals. I expect Dr. Liau and the entire group of doctors to publish DCVax no matter what.
I try not to find false reasons to presume success. I think the blinded data is adequate enough to fell fairly confident. But these other proxies, relying on laws that are not really what they are billed to be, or the assumption that a trial would not ever by published if it failed, are not useful measures for presuming “success”.
Also, I’ve learned over the years that superficially “obviously failed” trials are often not necessarily a complete failure and sometimes drugs eventually are approved out of that data.
People on bulletin boards and the markets operate in black and whites and shorts love to manipulate those feelings. Longs love to grasp at straws. What we have is extremely exciting blinded measures that clearly suggest that something dramatically good is happening with the patients in the trial. Once they release the data, we will have a fuller picture. Then there will be a publication.
A publication on a failed trial is just as important as one on a successful trial, especially a trial this data rich and important. So I’d presume it gets published no matter what.
I also think the company INTENDS to tell us the top line results as soon as they can, because they have said they will, repeatedly.
News 
Market Data 
Discover 
AI
